

- (51) International Patent Classification:  
A61K 38/30 (2006.01) C07K 14/65 (2006.01)  
A61K 9/00 (2006.01) C07K 38/18 (2006.01)  
A61P 21/00 (2006.01)

(21) International Application Number:  
PCT/US2024/045683

(22) International Filing Date:  
06 September 2024 (06.09.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/581,262 07 September 2023 (07.09.2023) US

(71) Applicant: JUVENA THERAPEUTICS, INC. [US/US];  
640 Galveston Drive, Redwood City, California 94063 (US).

(72) Inventor: O'CONNELL, Jeremy; 640 Galveston Drive,  
Redwood City, California 94063 (US).

(74) Agent: MAY, Scott et al.; Wilson Sonsini Goodrich &  
Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).


(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:  
— as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))  
— of inventorship (Rule 4.17(iv))

Published:  
— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

(54) Title: IGF2 FUSION PROTEIN FORMULATIONS AND THERAPEUTIC USES THEREOF



(57) Abstract: Provided herein, in certain aspects, are pharmaceutical compositions comprising an HSA-IGF2 fusion protein formulated for subcutaneous administration. As provided herein, are methods of treating muscle disorders, including myotonic dystrophies, comprising administration of a pharmaceutical composition comprising an HSA-IGF2 fusion protein formulated for subcutaneous administration.